EA201590920A1 - Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ - Google Patents
Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназInfo
- Publication number
- EA201590920A1 EA201590920A1 EA201590920A EA201590920A EA201590920A1 EA 201590920 A1 EA201590920 A1 EA 201590920A1 EA 201590920 A EA201590920 A EA 201590920A EA 201590920 A EA201590920 A EA 201590920A EA 201590920 A1 EA201590920 A1 EA 201590920A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- heteroaryl
- substituted pyridyl
- compounds applied
- kinase modulators
- pyridyl compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
В изобретении предусматриваются соединения формулыили их стереоизомеры или фармацевтически приемлемые соли, где Rобозначает моноциклическую гетероарильную группу, a R, R, R, Rи Rимеют значение по определению в данной заявке, применимые в качестве модуляторов киназ, включая ингибирование IRAK-4.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261723848P | 2012-11-08 | 2012-11-08 | |
US201361774824P | 2013-03-08 | 2013-03-08 | |
PCT/US2013/068875 WO2014074675A1 (en) | 2012-11-08 | 2013-11-07 | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201590920A1 true EA201590920A1 (ru) | 2015-09-30 |
EA024940B1 EA024940B1 (ru) | 2016-11-30 |
Family
ID=49667571
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201590920A EA024940B1 (ru) | 2012-11-08 | 2013-11-07 | Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ |
Country Status (21)
Country | Link |
---|---|
US (3) | US9657009B2 (ru) |
EP (1) | EP2917206B1 (ru) |
JP (1) | JP6204484B2 (ru) |
KR (1) | KR20150079963A (ru) |
CN (1) | CN104781254B (ru) |
AU (1) | AU2013341200A1 (ru) |
BR (1) | BR112015009850A2 (ru) |
CA (1) | CA2890983A1 (ru) |
CL (1) | CL2015001249A1 (ru) |
CO (1) | CO7400871A2 (ru) |
EA (1) | EA024940B1 (ru) |
ES (1) | ES2615302T3 (ru) |
HK (1) | HK1213895A1 (ru) |
IL (1) | IL238609A0 (ru) |
MX (1) | MX2015005562A (ru) |
PE (1) | PE20150953A1 (ru) |
PH (1) | PH12015501005A1 (ru) |
SG (1) | SG11201503397YA (ru) |
TN (1) | TN2015000175A1 (ru) |
TW (1) | TW201427953A (ru) |
WO (1) | WO2014074675A1 (ru) |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9546153B2 (en) | 2012-11-08 | 2017-01-17 | Bristol-Myers Squibb Company | Bicyclic heterocycle substituted pyridyl compounds useful as kinase modulators |
WO2014074675A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
KR102527797B1 (ko) | 2012-12-21 | 2023-05-03 | 길리애드 사이언시즈, 인코포레이티드 | 폴리시클릭-카르바모일피리돈 화합물 및 그의 제약 용도 |
NO2865735T3 (ru) | 2013-07-12 | 2018-07-21 | ||
TW201609693A (zh) * | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
TW201613936A (en) | 2014-06-20 | 2016-04-16 | Gilead Sciences Inc | Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide |
TWI744723B (zh) * | 2014-06-20 | 2021-11-01 | 美商基利科學股份有限公司 | 多環型胺甲醯基吡啶酮化合物之合成 |
NO2717902T3 (ru) | 2014-06-20 | 2018-06-23 | ||
WO2016210034A1 (en) | 2015-06-24 | 2016-12-29 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
WO2016210036A1 (en) | 2015-06-24 | 2016-12-29 | Bristol-Myers Squibb Company | Heteroaryl substituted aminopyridine compounds |
ES2822956T3 (es) * | 2015-06-24 | 2021-05-05 | Bristol Myers Squibb Co | Compuestos de aminopiridina sustituidos con heteroarilo |
US10428026B2 (en) | 2015-09-02 | 2019-10-01 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
WO2017050714A1 (en) | 2015-09-22 | 2017-03-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridinone dicarboxamide for use as bromodomain inhibitors |
US10471050B2 (en) | 2015-10-05 | 2019-11-12 | Glaxosmithkline Intellectual Property (No.2) Limited | 2-OXO-1,2-dihydropyridine-3,5-dicarboxamide compounds as bromodomain inhibitors |
PT3380465T (pt) * | 2015-11-26 | 2020-10-23 | Novartis Ag | Derivados de diamino piridina |
CN108884070B (zh) | 2016-04-07 | 2021-07-02 | 葛兰素史克知识产权第二有限公司 | 作为溴结构域抑制剂的吡啶基衍生物 |
WO2017202742A1 (en) * | 2016-05-24 | 2017-11-30 | Glaxosmithkline Intellectual Property (No.2) Limited | Pyridine dicarboxamide derivatives as bromodomain inhibitors |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
JOP20190192A1 (ar) | 2017-03-01 | 2019-08-08 | Glaxosmithkline Ip No 2 Ltd | مشتقات بيرازول بوصفها مثبطات برومودومين |
GB201703282D0 (en) | 2017-03-01 | 2017-04-12 | Glaxosmithkline Intellectual Property (No 2) Ltd | Compounds |
LT3621960T (lt) | 2017-05-11 | 2021-10-11 | Bristol-Myers Squibb Company | Tienopiridinai ir benzotiofenai, naudingi kaip irak4 inhibitoriai |
JP2020524691A (ja) | 2017-06-21 | 2020-08-20 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | IRAK4調節因子としてのピラゾロ[1,5a]ピリミジン誘導体 |
WO2018234342A1 (en) | 2017-06-21 | 2018-12-27 | F. Hoffmann-La Roche Ag | ISOINDOLINONE DERIVATIVES AS MODULATORS OF IRAK4 |
US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
JP2021508703A (ja) * | 2017-12-26 | 2021-03-11 | カイメラ セラピューティクス, インコーポレイテッド | Irak分解剤およびそれらの使用 |
US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
US11485743B2 (en) | 2018-01-12 | 2022-11-01 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
US20210355088A1 (en) * | 2018-09-07 | 2021-11-18 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Brd4-jak2 inhibitors |
US20220119370A1 (en) * | 2018-09-07 | 2022-04-21 | H. Lee Moffitt Cancer Center And Reseach Institute, Inc. | Brd4-jak2 inhibitors |
CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
KR20220041124A (ko) * | 2019-07-23 | 2022-03-31 | 브리스톨-마이어스 스큅 컴퍼니 | Irak4 억제제로서 유용한 티에노피리디닐 및 티아졸로피리디닐 화합물 |
WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
US11779578B2 (en) | 2019-12-17 | 2023-10-10 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
IL294251A (en) | 2019-12-23 | 2022-08-01 | Blueprint Medicines Corp | Inhibitors of mutant forms of egfr |
TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
WO2022133046A2 (en) * | 2020-12-16 | 2022-06-23 | Ifm Due, Inc. | Compounds and compositions for treating conditions associated with sting activity |
WO2023092034A1 (en) * | 2021-11-17 | 2023-05-25 | Northwestern University | Wt-idh1 inhibition using a covalent and brain-penetrant small molecular inhibitor for ferroptosis induction in high-grade glioma |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60232510D1 (de) | 2001-06-15 | 2009-07-16 | Vertex Pharma | 5-(2-aminopyrimidin-4-yl)benzisoxazole als proteinkinasehemmer |
AUPR688101A0 (en) | 2001-08-08 | 2001-08-30 | Luminis Pty Limited | Protein domains and their ligands |
GB0211019D0 (en) | 2002-05-14 | 2002-06-26 | Syngenta Ltd | Novel compounds |
WO2004002964A1 (ja) | 2002-06-28 | 2004-01-08 | Yamanouchi Pharmaceutical Co., Ltd. | ジアミノピリミジンカルボキサミド誘導体 |
MXPA05007503A (es) | 2003-01-17 | 2005-09-21 | Warner Lambert Co | Heterociclicos 2-aminopiridina sustituidos como inhibidores de proliferacion celular. |
CN1820001A (zh) | 2003-07-10 | 2006-08-16 | 神经能质公司 | 经取代的杂环二芳基胺类似物 |
GB0402653D0 (en) | 2004-02-06 | 2004-03-10 | Cyclacel Ltd | Compounds |
US7521457B2 (en) | 2004-08-20 | 2009-04-21 | Boehringer Ingelheim International Gmbh | Pyrimidines as PLK inhibitors |
FR2896503B1 (fr) | 2006-01-23 | 2012-07-13 | Aventis Pharma Sa | Nouveaux derives soufres d'uree cyclique, leur preparation et leur utilisation pharmaceutique comme inhibiteurs de kinases |
EP2164841A1 (en) | 2007-06-08 | 2010-03-24 | Bayer CropScience SA | Fungicide heterocyclyl-pyrimidinyl-amino derivatives |
WO2009046416A1 (en) | 2007-10-05 | 2009-04-09 | Targegen Inc. | Anilinopyrimidines as jak kinase inhibitors |
GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
EP2070924A1 (de) | 2007-12-10 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Neue 2-Hetarylthiazol-4-carbonsäureamid-Derivative, deren Herstellung und Verwendung als Arzneimittel |
CA2745004C (en) | 2008-11-28 | 2014-07-15 | Kowa Company, Ltd. | Pyridine-3-carboxyamide derivative |
WO2010144647A1 (en) | 2009-06-12 | 2010-12-16 | Bristol-Myers Squibb Company | Nicotinamide compounds useful as kinase modulators |
JP5770198B2 (ja) | 2009-10-30 | 2015-08-26 | ヤンセン ファーマシューティカ エヌ.ベー. | オピオイド受容体調節因子としてのフェノキシ置換ピリミジン |
KR20120130104A (ko) | 2010-02-01 | 2012-11-28 | 닛뽕 케미파 가부시키가이샤 | Gpr119 작동약 |
EP2545037A1 (en) * | 2010-03-10 | 2013-01-16 | Ingenium Pharmaceuticals GmbH | Inhibitors of protein kinases |
MX2013012588A (es) | 2011-04-29 | 2014-05-20 | Icahn School Med Mount Sinai | Inhibidores de cinasa. |
EP2802579B1 (en) | 2012-01-13 | 2016-04-13 | Bristol-Myers Squibb Company | Thiazolyl- or thiadiazolyl-substituted pyridyl compounds useful as kinase inhibitors |
WO2013106614A1 (en) | 2012-01-13 | 2013-07-18 | Bristol-Myers Squibb Company | Triazolyl-substituted pyridyl compounds useful as kinase inhibitors |
CN104159896B (zh) | 2012-01-13 | 2017-05-24 | 百时美施贵宝公司 | 用作激酶抑制剂的杂环取代的吡啶基化合物 |
WO2014074675A1 (en) | 2012-11-08 | 2014-05-15 | Bristol-Myers Squibb Company | Heteroaryl substituted pyridyl compounds useful as kinase modulators |
MX2015005272A (es) * | 2012-11-08 | 2015-07-14 | Squibb Bristol Myers Co | Compuestos de piridilo sustituidos con alquilamida utiles como moduladores de las respuestas de interleucina 12 (il-12), interleucina 23 (il-23) y/o interferon alfa (ifnalfa). |
TW201609693A (zh) | 2014-01-03 | 2016-03-16 | 必治妥美雅史谷比公司 | 雜芳基取代之菸鹼醯胺化合物 |
-
2013
- 2013-11-07 WO PCT/US2013/068875 patent/WO2014074675A1/en active Application Filing
- 2013-11-07 ES ES13795914.4T patent/ES2615302T3/es active Active
- 2013-11-07 JP JP2015541886A patent/JP6204484B2/ja not_active Expired - Fee Related
- 2013-11-07 CN CN201380058618.7A patent/CN104781254B/zh active Active
- 2013-11-07 CA CA2890983A patent/CA2890983A1/en not_active Abandoned
- 2013-11-07 EA EA201590920A patent/EA024940B1/ru not_active IP Right Cessation
- 2013-11-07 TW TW102140575A patent/TW201427953A/zh unknown
- 2013-11-07 BR BR112015009850A patent/BR112015009850A2/pt not_active IP Right Cessation
- 2013-11-07 MX MX2015005562A patent/MX2015005562A/es unknown
- 2013-11-07 KR KR1020157014808A patent/KR20150079963A/ko not_active Application Discontinuation
- 2013-11-07 AU AU2013341200A patent/AU2013341200A1/en not_active Abandoned
- 2013-11-07 EP EP13795914.4A patent/EP2917206B1/en active Active
- 2013-11-07 PE PE2015000613A patent/PE20150953A1/es not_active Application Discontinuation
- 2013-11-07 SG SG11201503397YA patent/SG11201503397YA/en unknown
- 2013-11-07 US US14/441,705 patent/US9657009B2/en active Active
-
2015
- 2015-05-04 IL IL238609A patent/IL238609A0/en unknown
- 2015-05-06 PH PH12015501005A patent/PH12015501005A1/en unknown
- 2015-05-07 TN TNP2015000175A patent/TN2015000175A1/fr unknown
- 2015-05-08 CL CL2015001249A patent/CL2015001249A1/es unknown
- 2015-06-03 CO CO15127843A patent/CO7400871A2/es unknown
-
2016
- 2016-02-22 HK HK16101951.7A patent/HK1213895A1/zh unknown
-
2017
- 2017-04-06 US US15/480,682 patent/US10023562B2/en active Active
-
2018
- 2018-06-15 US US16/009,389 patent/US10544133B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
PH12015501005A1 (en) | 2015-07-27 |
US20150284382A1 (en) | 2015-10-08 |
US20170210730A1 (en) | 2017-07-27 |
EP2917206B1 (en) | 2016-12-21 |
CO7400871A2 (es) | 2015-09-30 |
MX2015005562A (es) | 2015-07-23 |
US10544133B2 (en) | 2020-01-28 |
AU2013341200A1 (en) | 2015-07-02 |
JP2016501186A (ja) | 2016-01-18 |
ES2615302T3 (es) | 2017-06-06 |
CL2015001249A1 (es) | 2015-07-31 |
IL238609A0 (en) | 2015-06-30 |
HK1213895A1 (zh) | 2016-07-15 |
BR112015009850A2 (pt) | 2017-07-11 |
TW201427953A (zh) | 2014-07-16 |
EP2917206A1 (en) | 2015-09-16 |
SG11201503397YA (en) | 2015-05-28 |
TN2015000175A1 (en) | 2016-10-03 |
WO2014074675A1 (en) | 2014-05-15 |
PE20150953A1 (es) | 2015-06-20 |
US9657009B2 (en) | 2017-05-23 |
EA024940B1 (ru) | 2016-11-30 |
US20180370956A1 (en) | 2018-12-27 |
CN104781254A (zh) | 2015-07-15 |
CN104781254B (zh) | 2016-12-14 |
JP6204484B2 (ja) | 2017-09-27 |
KR20150079963A (ko) | 2015-07-08 |
US10023562B2 (en) | 2018-07-17 |
CA2890983A1 (en) | 2014-05-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201590920A1 (ru) | Гетероарилзамещённые пиридильные соединения, применимые в качестве модуляторов киназ | |
PH12018500341A1 (en) | Heterocyclic amides as kinase inhibitors | |
PH12019501321A1 (en) | Methods of treating or preventing cholesterol related disorders | |
MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
MY182082A (en) | Biheteroaryl compounds and uses thereof | |
UA111382C2 (uk) | Інгібітори протеїнкінази | |
MA39749A (fr) | Dérivés de pipéridine-dione | |
IN2015DN00598A (ru) | ||
MX2015002040A (es) | Baricitinib deuterado. | |
MX345552B (es) | Compuestos heterocíclicos útiles para inhibición de cinasa. | |
CR20140468A (es) | Inhibidores de diacilglicerol aciltransferasa 2 | |
EP3057962A4 (en) | Hydrochloride salt form for ezh2 inhibition | |
EA201591634A1 (ru) | Дигидропиридопиримидиновые соединения | |
MX2015011456A (es) | Derivados de 3-(arilo o heteroailo) metilenindolino-2-ona como inhibidores de cinasas de la via de las celulas madres cancerosas para el tratamiento del cancer. | |
EA201890820A1 (ru) | НОВЫЕ ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА В КАЧЕСТВЕ ДВОЙСТВЕННЫХ ИНГИБИТОРОВ DYRK1/CLK1 | |
MX341456B (es) | Amino-quinolinas como inhibidores de cinasa. | |
EA201590552A1 (ru) | Аминохинолины в качестве ингибиторов киназы | |
JO3318B1 (ar) | مثبطات bace | |
EP3541806A4 (en) | HETEROCYCLIC COMPOUNDS AS KINASE INHIBITORS | |
MX2015016332A (es) | Inhibidores de alk biciclicos fusionados. | |
MX2015008829A (es) | Momelotinib deuterado. | |
EA201600123A1 (ru) | Производные 1-(пиперазин-1-ил)-2-([1,2,4]триазол-1-ил)этанона | |
MX2015012610A (es) | Pacritinib deuterizado. | |
UA89428U (en) | 2-(14,15-dioxa-7-azadispirro[5,1,5,2]pentadec -7-yl)ethanol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |